Hoping to challenge blockbuster breast cancer franchises, a small Dutch biotech says its ADC passed a PhIII test

For the last several years, an under-the-radar challenger to Big Pharma’s breast cancer franchises has been working on an antibody drug conjugate involving Herceptin. On Tuesday, the Dutch biotech revealed the program had met its primary endpoint in a Phase III study, and they say they’re ready to make a deal.